Search

For sustainability of life and rural development, assessment of fruits in a non-destructive manner is required. The fruits which are available in the market must fulfill buyer needs. Orange fruit analysis is generally done by visual examination and by observing the size. For large volumes, we cannot assess by human graders, so picture preparation is done on quantitative, solid, and predictable data. This research contains a division of orange images based on fresh and rotten criteria, the images are of different kind based on the rotation of images. Then the classification of images is done based on CNN, binary cross-entropy loss function, along with accuracy is calculated and resultant graphs are illustrated with an accuracy of 78.57%.

The production of rice grain plays a major role in the global economy. In this context, there is a high demand to focus on yield production of staple food. In general, paddy crop fields undergo biotic stress which adversely affects stages of the growth of a plant which in turn leads to the low production of the crop. Conventional methods used to identify the biotic stress must rely on the experts manually through observations in the crop field, which isn’t that reliable since there is a chance of error-prone observations that leads to the incorrect management of biotic stress management. We present a new approach to the development of the biotic stress prediction model, based on rice disease image classification, using deep convolutional networks. Preliminary steps required to perform the proposed method are the collection of datasets from different sources, deep learning framework to perform the training. The developed model can recognize different types of biotic stress out of diseased and healthy leaves which resulted in an accuracy of 98.33%.

Context: Therapeutic wounding includes wounding the skin to induce pigmentation of the depigmented skin patches that was earlier used for repigmenting small patches of stable vitiligo. In this study, we have used the same principle to induce pigmentation in idiopathic guttate hypomelanosis (IGH) by spot peel with 88% phenol. Aims: To study the efficacy of phenol in causing repigmentation in IGH and its adverse effect profile. Settings and Design: Open prospective study. Materials and Methods: Twenty patients with 139 IGH macules were subjected to spot peel. Eighty-eight percent phenol was applied with an ear bud once a month for two sittings. Patients were assessed both subjectively and objectively after every session and at the end of 3 months of initiation of therapy. Results: Repigmentation was noted in 64% of IGH macules. More than 75% improvement was seen in 45% of the total IGH macules, while 41.5% showed 50-75% improvement at the end of three months. Persistent scabbing was the common adverse effect noted in 17.26% of lesions. Conclusion: Spot peel with 88% phenol is a safe, simple, cost-effective, outpatient procedure for IGH, which can be combined with other medical therapies.

Title: Secukinumab efficacy and safety in Indian patients with moderate-to-severe plaque psoriasis: sub-analysis from FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), a randomized, placebo-controlled, phase 3 study. Background: Evidence has suggested Interleukin (IL)-17A to be an important effector cytokine in the pathogenesis of psoriasis. Here, we report results for an Indian sub-population from a multinational study FIXTURE, designed to assess the safety, tolerability, and long-term efficacy of fully human anti–IL-17A monoclonal antibody secukinumab in patients with moderate-to-severe plaque psoriasis. Materials and Methods: In this double-dummy, placebo controlled, 52-weeks phase 3 study FIXTURE, 149 Indian patients were randomized 1:1:1:1 to receive secukinumab at a dose of 300 mg or 150 mg, etanercept, or placebo. The study objective was to show the superiority of secukinumab over placebo at week 12, vis-à-vis proportion of patients achieving a reduction of 75% or more from the baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (IGA mod 2011) (co-primary end points). Results: At week 12, 61.0% and 55.9% patients in secukinumab 300 mg and 150 mg groups, respectively, achieved PASI 75 response compared to 20.0% in the etanercept and 7.1% in the placebo groups. Similarly, IGA mod 2011 0 or 1 response was achieved by 43.9% and 20.6% in patients in the secukinumab 300 mg and 150 mg group, respectively, vs. 13.3% in the etanercept and 2.4% in the placebo groups at week 12. Likewise, higher proportions of patients in secukinumab 300 mg (41.5%) and 150 mg (20.6%) group were PASI 90 responders at week 12 than those in the etanercept (10.0%) or placebo (0.0%) groups. The incidences of adverse events (AEs), during the induction period were similar in all the treatment groups. Overall secukinumab was well-tolerated at both doses in the Indian sub-population. Conclusion: The results from the Indian sub-population suggest that secukinumab is an efficacious and safe drug for use in moderate-to-severe chronic plaque psoriasis

A case of Cryptococcus neoformans causing localized cutaneous lesion over the left upper lip in an acquired immunodeficiency syndrome (AIDS) patient with cryptocococcal meningitis and pulmonary tuberculosis.